Participated · Equity · Jun 2026

Founded in 2023 by Anton Gladkoborodov and Oleg Shevlyagin and based in New York, Corca Research builds a collaborative workspace for mathematics that combines WYSIWYG math editing, real-time collaboration, and built-in AI assistance. Its platform’s AI features help solve problems, manipulate expressions, and generate code so users can work without switching tools. The company emphasizes making mathematical work faster and computationally connected through integrated tooling. The recent $7.8M financing is intended to accelerate product development, bolster AI capabilities, and expand the engineering team. The article does not disclose revenue, users, or other financial operating metrics. Corca has institutional backers including NEA, Bloomberg Beta, Daft Capital, and NVentures.

Led · Equity · May 2026

Founded in 2023 by Johan Outinen and David Wedar and led by CEO Johan Outinen, Elvy sells subscription-based home energy packages in which it owns the hardware and provides installation, maintenance and a 15-year service contract. Its offering bundles solar panels, heat pumps and battery systems and is managed by a proprietary AI engine that controls and optimizes household energy generation and consumption. The company reported its subscription model grew 10x in 2025 and has built 23 MW of capacity in its distributed energy park in just over 18 months. Elvy has secured a €500 million credit facility from Scayl to fund hardware deployment at scale and has now closed a €5.9 million equity round to accelerate growth. Management says the company is prepared to invest over €1 billion and secure 600 MW within three years, and has added Knut Frängsmyr as Chairman to support that expansion.

Participated · Seed · May 2026

Scarlet Therapeutics develops red blood cell therapies produced from immortalized cell lines to create scalable, off-the-shelf biologic products. Its lab-grown RBCs have, in preclinical studies, matured and circulated in vivo with a half-life comparable to donated red blood cells. The company modifies RBCs to convert toxic metabolites and is targeting indications including hyperammonemia and hyperoxaluria. Because it uses immortalized master cell banks, Scarlet aims to avoid donor-sourced scalability and reproducibility issues and to manufacture at large scale. Scarlet plans quarterly dosing of its RBC products and is advancing process development and regulatory interactions to support a clinical path. The recent £3.2 million seed raise will fund animal studies in three indications and help position the company for a follow-on financing once a lead program is selected.